Compare Novavax Inc (NVAX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 72.8× Novavax Inc's market cap, and State Street Technology Select Sector SPDR ETF is more actively traded (9,063,135 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| NVAX | XLK | |
|---|---|---|
Market Cap | $1.82B | $132.55B |
Volume | 6,198,505 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $12.75 | $202.00 |
52-Week Low | $6.22 | $127.49 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
XLK trades at $197.79, down 1.79% on the day, with a bullish technical signal driven by moving averages. The ETF shows neutral oscillators and key support at $196. Recent news highlights concentration risks in its holdings, with some analysts favoring alternative tech ETFs for better diversification. Dividend activity is scheduled for late 2026.
Outlook remains cautiously optimistic given bullish technicals, but concentration in chip stocks poses a risk. Opportunities include AI-driven growth exposure, while risks involve interest rate sensitivity and sector-specific volatility. Investors should weigh diversification against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
